In brief: Suspension of Johnson & Johnson COVID-19 vaccine lifted.
出版信息
Med Lett Drugs Ther. 2021 May 17;63(1624):e1.
PMID:33976095
Abstract
摘要
相似文献
1
In brief: Suspension of Johnson & Johnson COVID-19 vaccine lifted.简而言之：强生公司新冠疫苗的暂停使用解除。
Med Lett Drugs Ther. 2021 May 17;63(1624):e1.
2
In brief: Johnson & Johnson COVID-19 vaccine suspended.简而言之：强生新冠疫苗暂停使用。
Med Lett Drugs Ther. 2021 May 3;63(1623):e1.
3
FDA authorizes Johnson & Johnson COVID-19 vaccine.美国食品药品监督管理局批准强生公司的新冠疫苗。
Med Lett Drugs Ther. 2021 Mar 22;63(1620):41-42.
4
In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons.简而言之：为免疫功能低下者接种第三剂基于mRNA的新冠疫苗。
Med Lett Drugs Ther. 2021 Sep 20;63(1633):145-146.
5
In brief: Guillain-Barré syndrome with the Johnson and Johnson COVID-19 vaccine.简而言之：吉兰-巴雷综合征与强生公司的新冠疫苗。
Med Lett Drugs Ther. 2021 Aug 9;63(1630):121.
6
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.美国 2021 年 4 月：在报告接种强生（Johnson & Johnson）新冠疫苗的人群中出现血栓性血小板减少综合征后，免疫实践咨询委员会更新了强生疫苗的使用建议。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.
7
Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply.增加有限新冠疫苗供应效益的替代剂量分配策略
Ann Intern Med. 2021 Apr;174(4):570-572. doi: 10.7326/M20-8137. Epub 2021 Jan 5.
8
Answering Key Questions About COVID-19 Vaccines.解答关于新冠疫苗的关键问题。
JAMA. 2020 Nov 24;324(20):2027-2028. doi: 10.1001/jama.2020.20590.
9
Vaccine safety - is the SARS-CoV-2 vaccine any different?疫苗安全性 - SARS-CoV-2 疫苗有何不同？
Hum Vaccin Immunother. 2021 May 4;17(5):1322-1325. doi: 10.1080/21645515.2020.1829414. Epub 2020 Dec 3.
10
Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.接受生物制剂和某些其他全身治疗的皮肤科患者应接种一剂信使核糖核酸新冠病毒“加强针”疫苗：对美国食品药品监督管理局和免疫实践咨询委员会近期建议的批判性评估
J Am Acad Dermatol. 2021 Nov;85(5):1113-1116. doi: 10.1016/j.jaad.2021.08.031. Epub 2021 Aug 23.
Zotero 插件